Meet with our product experts in one-on-one virtual sessions
对我们的产品有疑问? 我们将尽早回复
CPHI China 2024
CPHI Japan 2024
CPHI JAPAN 2023
Korea Science Day 2023
DCAT 2023
MAGHREB PHARMA Expo 2023
CPHI Milan 2024
DCAT Week
CPHI Middle East 2024
DCAT 2024
CPhI North America
CPHI India
CPhI Korea
CPhI Worldwide
CPhI China
FCE Pharma 2022
CPhI NA
CPHI Worldwide 2023
Product Alert – Vonoprazan Fumarate
Presence of Organic Impurities in active pharmaceutical ingredients: An Overview
Strategies and Technologies for Enhancing Cost-Effectiveness in Active Pharmaceutical Ingredient (API) Production
Effective Formulation Development Strategies for Poorly Soluble Active Pharmaceutical Ingredients (APIs)
Impact of Venetoclax Exposure on Clinical Efficacy and Safety in Patients with Refractory Chronic Lymphocytic Leukemia
Demonstrating Equivalence of Generic Glatiramer Acetate: Ensuring Quality and Safety
Streamlining the Process: Preparing a Pharmaceutical Composition of Fosaprepitant API
Substantially Pure Carfilzomib Amorphous for Generic Launch
Semaglutide - Dr. Reddy’s Fully Synthetic Peptide API
Tech Sheet on Ibrutinib
Our experts will answer your questions, provide advice, and help you understand our product better
本目錄中的任何信息(包括對任何產品或服務的任何引用)均不構成銷售要約,或被解釋為代表銷售要約。受有效專利保護的產品不提供或供應用於商業用途。但是,只要存在此類監管豁免,就可以出於監管提交的目的提供此類產品的研究數量。買方應對各自市場的專利方案進行獨立評估,並承擔所有與專利相關的責任。在印度受有效專利保護的產品不可用於商業用途,但可用於第 107A 節。
Follow this page to explore how our offerings can accelerate your formulation success
Click here to visit